2023-05-24 09:12:18 ET
- GeoVax Labs ( NASDAQ: GOVX ) presents updates on its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial.
- The presentations at Vaccines Summit Boston 2023 and CYTO 2023 meetings feature unpublished data from the open-label portion of the Phase 2 trial in hematological cancer patients.
- Preliminary analysis shows that CM04S1 is highly immunogenic in these patients, inducing antibody responses and T cell responses, including neutralizing antibodies.
- The Phase 2 clinical study will progress with a direct comparison to currently approved mRNA vaccines.
- CM04S1 is also being evaluated as a booster for healthy patients who previously received the Pfizer or Moderna mRNA vaccine in a separate Phase 2 trial.
- Data from both trials will provide insights into vaccine potential in unique patient groups and the general population.
- ( GOVX ) has risen 2.3% premarket.
For further details see:
GeoVax Labs posts positive data on SARS-CoV-2 vaccine in phase 2 trial